Vyvanse Use in Pregnancy
If Vyvanse is required for daily functioning during pregnancy, it should not be stopped, as the documented risks are very low and do not appear to include major congenital malformations. 1
Key Safety Evidence
The 2024 American Journal of Obstetrics and Gynecology guidelines provide the most comprehensive and recent evidence on lisdexamfetamine (Vyvanse) in pregnancy 1:
Since lisdexamfetamine is a prodrug converted to dextroamphetamine, its safety profile mirrors that of amphetamines:
- No association with major congenital malformations including cardiac defects 1
- Possible small increased risks (but clinically debatable):
- Gastroschisis (aOR 3.0; 95% CI 1.2-7.4) - absolute risk remains extremely low at 0.05% population prevalence, likely confounded, other studies found no association 1
- Preeclampsia (aRR 1.29; 95% CI 1.11-1.49) - small risk, other studies found no association 1
- Preterm birth when continued in second half of pregnancy (aRR 1.30; 95% CI 1.10-1.55) - small risk 1
Important context: A 2025 population-based cohort study found that ADHD medications do not increase risk of neurodevelopmental disorders in offspring, supporting long-term safety 2. The FDA label acknowledges limited data but notes no teratogenic signal in animal studies 3.
Clinical Decision Algorithm
Preconception Planning
- If medication is not severely impacting daily functioning: Consider gradual discontinuation trial before pregnancy 1
- If discontinuation is not feasible: Continue current medication OR reduce to lowest effective dose OR consider intermittent use OR switch to nonstimulant (though less efficacious) 1
- Engage in risk-benefit discussion regarding medication choice and dosing 1
During Pregnancy
- Continue Vyvanse if required for daily functioning - the consensus is clear that treatment should not be stopped when needed 1
- Consider intermittent/as-needed dosing to maximize functioning while reducing fetal exposure (stimulants have rapid effect) 1
- Alternative option: Switch to bupropion, particularly if co-occurring depression exists, though recognize it is less efficacious for ADHD 1
Monitoring Requirements During Pregnancy
- Fetal growth assessments 1
- Blood pressure checks 1
- Ensure appropriate maternal weight gain 1
- Monitor for preterm labor signs
At Delivery and Postpartum
The FDA label warns that amphetamines may decrease placental perfusion and stimulate uterine contractions 3. Monitor newborns for:
- Withdrawal symptoms (feeding difficulties, irritability, agitation, excessive drowsiness) 3
- Appropriate weight gain 1
- Developmental milestones 1
Breastfeeding Considerations
Breastfeeding safety with amphetamine derivatives requires discussion 1. The Hale lactation risk category is L3 1. While there are no published studies specifically on lisdexamfetamine during breastfeeding, amphetamine data suggest:
- Breastfeeding does not seem to adversely affect infants overall 1
- Monitor infant carefully for: irritability, insomnia, feeding difficulty 1
- Consider strategies: Intermittent use, timing feeding/pumping to achieve lowest concentration in milk 1
- One case report documented successful breastfeeding with lisdexamfetamine without observed infant side effects 4
The FDA label states that Vyvanse passes into breast milk and recommends discussing feeding options 3.
Critical Caveats
Confounding by indication: Many documented risks may be elevated in ADHD itself rather than directly attributable to medication 1. The magnitude of documented medication risks is arguably not clinically meaningful 1.
Miscarriage concern: One 2025 Norwegian study found increased miscarriage risk with ADHD medications (aOR 1.81 for lisdexamfetamine), with dose-response relationship 5. However, filled prescriptions may not reflect actual use, and this requires further clarification.
Pregnancy registry: Encourage enrollment in the National Pregnancy Registry for Psychostimulants (1-866-961-2388) 3.
Untreated ADHD risks: Discontinuing treatment can impair occupational functioning, driving safety, and overall maternal well-being, potentially placing both mother and baby at risk 6, 7. This must be weighed against medication risks in shared decision-making.